We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Read MoreHide Full Article
Key Takeaways
TG Therapeutics could benefit from strong Briumvi demand, with an Earnings ESP of 71.43%.
Immunome advances varegacestat toward potential U.S. and European approvals for desmoid tumors.
REGENXBIO's late-stage gene therapy pipeline supports its growth prospects, with an Earnings ESP of 6.53%.
The third-quarter 2026 earnings season is currently in full swing. The scorecard for the Medical sector has been encouraging so far. The sector primarily comprises pharma/biotech and medical device companies.
The earnings season for the pharma/biotech sector kicked off last month when pharma bellwether Johnson & Johnson beat on earnings but marginally missed on sales in the third quarter. Swiss pharma giant Novartis also beat earnings estimates but missed sales projections in the quarter. On the biotech front, Bristol-Myers (BMY - Free Report) beat earnings and revenue estimates, driven by Growth Portfolio strength and Eliquis demand. Biogen also posted strong results, beating both earnings and sales estimates.
The Earnings Trends report indicates that, as of Oct. 28, 26.7% of the companies in the Medical sector, representing about 33.1% of the sector’s market capitalization, have reported quarterly earnings. While 81.3% of the companies topped earnings estimates, 93.8% beat on sales. While earnings increased 8.1% year over year, sales grew 2.7%. Overall, third-quarter earnings are expected to fall 0.9% year over year, while revenues are likely to rise 5%.
Zeroing in on Winners
Although some major biotechnology companies have already reported their results, several others are yet to announce their earnings. Some of them seem poised to surpass estimates for the quarter. We have highlighted four biotech companies, TG Therapeutics (TGTX - Free Report) , Immunome (IMNM - Free Report) , REGENXBIO (RGNX - Free Report) and Promis Neurosciences (PMN - Free Report) , which are expected to deliver an earnings beat this reporting cycle.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance of delivering an earnings surprise. It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that the chance of an earnings surprise for stocks with this combination is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
4 Biotech Stocks That Match the Criteria
TG Therapeutics
TGTX is a commercial-stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Continued robust demand for lead drug, Briumvi, (relapsing multiple sclerosis) in the United States has likely driven top-line revenue growth in the third quarter. Pipeline progress also remains in spotlight.
TGTX has an Earnings ESP of +71.43% and a Zacks Rank of 1 at present. The Zacks Consensus Estimate for revenues in the to-be-reported quarter is pegged at $247.16 million, while the same for earnings is pinned at 37 cents per share.
TGTX is scheduled to report third-quarter results on Nov. 9.
TG Therapeutics, Inc. Price, Consensus and EPS Surprise
Immunome is a clinical-stage oncology company focused on developing targeted cancer therapies. It is advancing varegacestat toward potential U.S. and European approvals for desmoid tumors. The FDA accepted its new drug application in July 2026, with a target action date of April 28, 2027, while the European Medicines Agency has validated its Marketing Authorization Application.
REGENXBIO is a biotechnology company developing a late-stage pipeline of one-time gene therapies for rare and retinal diseases. Its key candidates include RGX-202 for Duchenne muscular dystrophy; clemidsogene lanparvovec (RGX-121) for MPS II and RGX-111 for MPS I, both being developed in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for wet age-related macular degeneration (AMD) and diabetic retinopathy, in collaboration with AbbVie.
RGNX has an Earnings ESP of +6.53% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for revenues is pegged at $9.6 million, while the same for earnings is pinned at a loss of $1.35 per share.
RGNX is scheduled to report third-quarter results on Nov. 5.
ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody-based therapies and vaccines targeting toxic protein oligomers associated with neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS. Its proprietary EpiSelect platform identifies disease-specific targets on misfolded proteins. Its lead candidate, PMN310, is a phase Ib humanized monoclonal antibody designed to selectively target toxic amyloid-beta oligomers implicated in Alzheimer's disease while sparing amyloid plaques and vascular deposits.
Promis Neurosciences Price, Consensus and EPS Surprise
View the Zacks #1 Rank List
Image: Bigstock
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Key Takeaways
The third-quarter 2026 earnings season is currently in full swing. The scorecard for the Medical sector has been encouraging so far. The sector primarily comprises pharma/biotech and medical device companies.
The earnings season for the pharma/biotech sector kicked off last month when pharma bellwether Johnson & Johnson beat on earnings but marginally missed on sales in the third quarter. Swiss pharma giant Novartis also beat earnings estimates but missed sales projections in the quarter. On the biotech front, Bristol-Myers (BMY - Free Report) beat earnings and revenue estimates, driven by Growth Portfolio strength and Eliquis demand. Biogen also posted strong results, beating both earnings and sales estimates.
The Earnings Trends report indicates that, as of Oct. 28, 26.7% of the companies in the Medical sector, representing about 33.1% of the sector’s market capitalization, have reported quarterly earnings. While 81.3% of the companies topped earnings estimates, 93.8% beat on sales. While earnings increased 8.1% year over year, sales grew 2.7%. Overall, third-quarter earnings are expected to fall 0.9% year over year, while revenues are likely to rise 5%.
Zeroing in on Winners
Although some major biotechnology companies have already reported their results, several others are yet to announce their earnings. Some of them seem poised to surpass estimates for the quarter. We have highlighted four biotech companies, TG Therapeutics (TGTX - Free Report) , Immunome (IMNM - Free Report) , REGENXBIO (RGNX - Free Report) and Promis Neurosciences (PMN - Free Report) , which are expected to deliver an earnings beat this reporting cycle.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance of delivering an earnings surprise. It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that the chance of an earnings surprise for stocks with this combination is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
4 Biotech Stocks That Match the Criteria
TG Therapeutics
TGTX is a commercial-stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Continued robust demand for lead drug, Briumvi, (relapsing multiple sclerosis) in the United States has likely driven top-line revenue growth in the third quarter. Pipeline progress also remains in spotlight.
TGTX has an Earnings ESP of +71.43% and a Zacks Rank of 1 at present. The Zacks Consensus Estimate for revenues in the to-be-reported quarter is pegged at $247.16 million, while the same for earnings is pinned at 37 cents per share.
TGTX is scheduled to report third-quarter results on Nov. 9.
TG Therapeutics, Inc. Price, Consensus and EPS Surprise
TG Therapeutics, Inc. price-consensus-eps-surprise-chart | TG Therapeutics, Inc. Quote
Immunome
Immunome is a clinical-stage oncology company focused on developing targeted cancer therapies. It is advancing varegacestat toward potential U.S. and European approvals for desmoid tumors. The FDA accepted its new drug application in July 2026, with a target action date of April 28, 2027, while the European Medicines Agency has validated its Marketing Authorization Application.
IMNM has an Earnings ESP of +1.27% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for revenues is pegged at $2 million, while the same for earnings is pinned at a loss of 67 cents per share.
The company is expected to report third-quarter results later this week.
Immunome, Inc. Price, Consensus and EPS Surprise
Immunome, Inc. price-consensus-eps-surprise-chart | Immunome, Inc. Quote
REGENXBIO Inc.
REGENXBIO is a biotechnology company developing a late-stage pipeline of one-time gene therapies for rare and retinal diseases. Its key candidates include RGX-202 for Duchenne muscular dystrophy; clemidsogene lanparvovec (RGX-121) for MPS II and RGX-111 for MPS I, both being developed in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for wet age-related macular degeneration (AMD) and diabetic retinopathy, in collaboration with AbbVie.
RGNX has an Earnings ESP of +6.53% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for revenues is pegged at $9.6 million, while the same for earnings is pinned at a loss of $1.35 per share.
RGNX is scheduled to report third-quarter results on Nov. 5.
REGENXBIO Inc. Price, Consensus and EPS Surprise
REGENXBIO Inc. price-consensus-eps-surprise-chart | REGENXBIO Inc. Quote
ProMIS Neurosciences
ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody-based therapies and vaccines targeting toxic protein oligomers associated with neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS. Its proprietary EpiSelect platform identifies disease-specific targets on misfolded proteins. Its lead candidate, PMN310, is a phase Ib humanized monoclonal antibody designed to selectively target toxic amyloid-beta oligomers implicated in Alzheimer's disease while sparing amyloid plaques and vascular deposits.
Promis Neurosciences Price, Consensus and EPS Surprise
Promis Neurosciences price-consensus-eps-surprise-chart | Promis Neurosciences Quote
PMN has an Earnings ESP of +22.43% and a Zacks Rank of 2 at present.
It is scheduled to report third-quarter results on Nov. 12.